A primary challenge for genomics companies is the transition from obtaining sequence information to offering useful products. Integrated Genomics is attempting to add such value by providing customers not only with information about particular genes and their functions, but with an accompanying map of how these genes interact in an organism's metabolic pathways. By diagramming these control mechanisms, the company hopes to develop improved industrial processes involving microorganisms and, potentially, generate therapeutic targets.

"When we were formed, the field of service genomics was very crowded," said Yuri Nikolsky, a founder and vice president of business development. "We looked for what we could offer that goes beyond sequence information and analysis and decided upon improved enzymes and proteins and therapeutic targets."